Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 17;9(2):00584-2022.
doi: 10.1183/23120541.00584-2022. eCollection 2023 Mar.

ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly

Theodoros Karampitsakos  1 , Phuong Phuong Diep  2 , Daan W Loth  3 , Iftikhar Nadeem  4 , Elene Khurtsidze  5 , Marlies S Wijsenbeek  6 , Wim A Wuyts  7 , Elena Bargagli  8 , Antoine Froidure  9 , Paolo Spagnolo  10 , Marcel Veltkamp  11   12 , Maria Molina-Molina  13 , Cormac McCarthy  14 , Katerina M Antoniou  15 , Michael Kreuter  16 , Catharina C Moor  6
Affiliations

ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly

Theodoros Karampitsakos et al. ERJ Open Res. .

Abstract

This article contains a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the hybrid European Respiratory Society International Congress 2022. Early Career Members of Assembly 12 summarise recent advances in translational and clinical research in idiopathic interstitial pneumonias, ILDs of known origin, sarcoidosis and other granulomatous diseases, and rare ILDs. Many studies focused on evaluation of diagnostic and prognostic (bio)markers, and novel pharmacological and nonpharmacological treatment options for different ILDs. In addition, new insights in clinical, physiological and radiological features of various rare ILDs were presented.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: K.M. Antoniou has received consulting fees from BI, GSK and Roche, outside the submitted work; payment or honoraria from BI, Roche, Chiesi, Menarini, GSK and AstraZeneca, outside the submitted work. C. McCarthy has received grants or contracts from Health Research Board, Ireland, Enterprise Ireland and The LAM Foundation, outside the submitted work; consulting fees from Savara Inc., AI Therapeutics and Theravance Inc., outside the submitted work; support for attending meetings and/or travel from Boehringer Ingelheim, outside the submitted work; participation on a Data Safety Monitoring Board or Advisory Board for Savara Inc., outside the submitted work; and is a Breathe (published by ERS) editorial board member. M. Veltkamp has received consulting fees from Boehringer Ingelheim and Chiesi, outside the submitted work; payment or honoraria from Boehringer Ingelheim, outside the submitted work; participation on a data safety monitoring or advisory board for COLD study (Kalverda and Annema) on cryobiopsy in ILD, outside the submitted work. A. Froidure has received consulting fees from Boehringer Ingelheim and GlaxoSmithKline, outside the submitted work; payment or honoraria from Boehringer Ingelheim, outside the submitted work; and support for attending meetings and/or travel from Sanofi, outside the submitted work. M. Molina-Molina received grants or contracts from Boehringer Ingelheim, Roche, outside the submitted work; consulting fees from Ferrer, Boehringer Ingelheim, Roche, outside the submitted work; payment or honoraria from Chiesi, Roche, Boehringer Ingelheim outside the submitted work; and support for attending meetings and/or travel from Boehringer Ingelheim, outside the submitted work. W.A. Wuyts has received grants or contracts from Roche, Boehringer Ingelheim and Galapagos, outside the submitted work; consulting fees from Roche, Boehringer Ingelheim, Galapagos and Sanofi, outside the submitted work; participation on a data safety monitoring or advisory board for Roche, Boehringer Ingelheim and Sanofi, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: working group Belgian respiratory society (unpaid) and ERS group 12.1 (unpaid), outside the submitted work. D.W. Loth has received payment or honoraria from Boehringer Ingelheim B.V., outside the submitted work; support for attending meetings and/or travel from Boehringer Ingelheim B.V., outside the submitted work. E. Khurtsidze has received grants or contracts from Erasmus, outside the submitted work. M. Kreuter has received grants or contracts from Boehringer and Roche, outside the submitted work; consulting fees from Boehringer and Roche, outside the submitted work; payment or honoraria from Boehringer, Novartis, and Roche, outside the submitted work. P. Spagnolo has received grants or contracts from Roche, Boehringer Ingelheim and PPM Services, outside the submitted work; consulting fees from PPM Services, Chiesi, Galapagos, Behring, Santhera Pharmaceuticals and Novartis, outside the submitted work; payment or honoraria from Chiesi, Boehringer Ingelheim, outside the submitted work; participation on a data safety monitoring or advisory board for Galapagos, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group for ERS group 12.03 (Group chair, unpaid), outside the submitted work. P.P. Diep received payment or honoraria from Boehringer Ingelheim Norway, honoraria for presentations, outside the submitted work; support for attending the Nordic ILD-congress in Stockholm 2021, outside the submitted work. C.C. Moor has received grants or contracts from Boehringer Ingelheim, AstraZeneca and Daiichi-Sankyo, outside the submitted work; payment or honoraria from Boehringer Ingelheim, Hoffman–la Roche, outside the submitted work; ERS Early Career Member Committee, outside the submitted work. M.S. Wijsenbeek has received grants or contracts from Boehringer Ingelheim; Hoffman la Roche; The Netherlands Organisation for Health Research and Development; The Dutch Lung Foundation; The Dutch Pulmonary Fibrosis, outside the submitted work; consulting fees from Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, Hoffman la Roche, Horizon therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, and Respivant, outside the submitted work; payment or honoraria from Boehringer Ingelheim, CSL Behring, Hoffman la Roche and Novartis, outside the submitted work; support for attending meetings and/or travel from Boehringer Ingelheim and Hoffman la Roche Galapagos, outside the submitted work; participation on a data safety monitoring or advisory board for Savara, Galapagos, outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group for Chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society; member of the board of the Netherlands Respiratory Society; member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation; Chair of the educational committee of the European Reference Network for Rare Lung Diseases; advisory board of the Dutch Lungfibrosis and Sarcoidosis patient associations (unpaid), outside the submitted work. The remaining authors have nothing to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Randall M, De Bernard S, Seghers I, et al. . Assessment of a relationship between prognostic biomarkers and treatment response in ISABELA1&2 IPF cohorts. Eur Respir J 2022; 60: Suppl. 66, 846.
    1. van der Vis J, Prasse A, Renzoni E, et al. . Association of MUC5B rs35705950 minor allele with age and survival in European patients with idiopathic pulmonary fibrosis. Eur Respir J 2022; 60: Suppl. 66, 1044.
    1. Moor CC, Oppenheimer JC, Nakshbandi G, et al. . Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. Eur Respir J 2021; 57: 2002042. doi: 10.1183/13993003.02042-2020. - DOI - PubMed
    1. van der Sar IG, Moor CC, Vellekoop BPet al. . Predicting treatment response in patients with interstitial lung disease using electronic nose technology. Eur Respir J 2022; 60: Suppl. 66, 345.
    1. Myall K, Martinovic J, Wu Z, et al. . Nocturnal hypoxaemia is associated with mortality in patients with fibrotic interstitial lung disease. Eur Respir J 2022; 60: Suppl. 66, 1355.